Risk factor
Meaningful price volatility
Profitability factor
Greatly overvalued vs peers
About
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. It offers pathological diagnostic reagents and ancillary equipment, including liquid-based cytology, such as gynecological series, non-gynecological series, and equipment; fluorescence in situ hybridization products for various applications in breast, bladder, lung, cervical, prostate, and thyroid cancer; and neuroblastoma, soft tissue sarcoma, other solid tumors, prenatal screening and abortion, oligodendrocytes tumor, lymphoma, multiple myeloma, chronic myelogenous and lymphocytic leukemia, myelodysplastic syndromes, acute myeloid leukemia, and acute lymphoblastic leukemia. The company also provides immunohistochemistry products, which comprise antibodies, detection systems, repair systems, complementary products, and immunohistochemistry kit, as well as molecular genetic diagnosis products. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Buy
Sell